75 results about "Cancer development" patented technology

The uses of mono acetyl diacyl glycerol derivatives extracted from deer antler for immunomodulating agent disclosed. Medical supplies and health foods containing the same as an effective ingredient also disclosed. Mono acetyl diacyl glycerol derivatives shows significantly effect for immuno modulation including immune enhancing. In the case of inducing cancer in a hamster by injecting cancer cell line, cancer development was delayed by activating lymphocytes, monocytes, and dendritic cells that are important factors to promote immunity and apoptosis of cancer cell was induced by promoting cytotoxicity of immune cell against cancer cell. Also in the case of mouse induced septic shock, it shows 100% survival rate even after lapse of 120 hours by control of immune function and suppression effect apoptosis. Therefore, mono acetyl diacyl glycerol derivatives according to the present invention can be effectively used for an immunomodulating agent, a sepsis treatment, a cancer treatment, and a health food for an immune modulation or the prevention of cancer.

The invention relates to a kit and method for the diagnosis of lung cancer in chronic obstructive pulmonary disease (COPD) patients through meta-genome analysis. The invention provides a kit for providing diagnosis information of lung cancer through bacteria meta-genome analysis. More specifically, the invention provides a kit for predicting the risk of lung cancer or diagnosing lung cancer basedon the increasing or decreasing of extracellular vesicles of specific bacteria of a sample of a tested patient through bacterial meta-genome analysis. The extracellular vesicles (EV) secreted from thebacteria present in an environment can be absorbed into the body and directly affect cancer development. Lung cancer is difficult to diagnose before symptoms occur, thereby making effective treatmentdifficult. According to the present invention, the meta-genomes of the extracellular vesicles (EV) present in the human-derived sample are analyzed to predict the risk of lung cancer, thereby predicting and diagnosing the risk groups of the lung cancer to prevent or delay the incidence of lung cancer through appropriate management. The present invention also enables early prediction even after the incidence to lower the incidence rate of the lung cancer and enhance the treatment effects.

Provided are recombinant polynucleotides, including expression vectors encoding an alpha chain and / or a beta chain of a TCR having amino acid sequences from any of novel the AL, KQ, PP, 19305CD8, BB,KB, ST, JD, 19305DP, PB-P, PB-T, and PB 13.2 T Cell Receptors (TCRs) that are embodiments of the invention. Cells comprising the polynucleotides are provided, as are libraries of the recombinant polynucleotides and expression vectors. Methods are provided and involve administering to an individual modified human T cells that express a novel recombinant TCR. The methods are for prophylaxis and / or therapy of an individual diagnosed with, suspected of having or at risk for developing or recurrence of a cancer, wherein the cancer includes cancer cells which express NY-ESO-1 and / or its highly homologous LAGE-1 antigen.

Gene probes for specific regions of chromosome 3 (3p21.3) and chromosome 10 (10q22) have been found to be tools for the diagnosis and prognosis of smoking related cancers such as non-small cell lung cancer (NSCLC). For example, these probes can be used with fluorescence in situ hybridization (FISH), and used to stratify smokers into high and low risk groups, as well as determine a patients susceptibility to the development of smoking related cancers.